Although CSF-soluble TREM2 (sTREM2) demonstrates correlations with tau burden in AD, its variable expression in PD and ALS, combined with confounding factors like the H157Y mutation that increases sTREM2 shedding, highlights the necessity of comprehensive longitudinal biomarker validation. The gene discussed is TREM2; the disease is Alzheimer disease.